Idioma:

Successful use of tralokinumab for the treatment of atopic dermatitis on the genitals

Paolino, Giovanni ; Narcisi, Alessandra ; Carugno, Andrea ; Malagoli, Piergiorgio ; Di Nicola, Matteo R ; Foti, Antonio ; Bianchi, Vittoria G ; Locatelli, Andrea Gustavo ; Sena, Paolo ; Costanzo, Antonio ; Mercuri, Santo R ; Valenti, Mario

The Journal of dermatological treatment, 2024-12, Vol.35 (1), p.2351489-2351489 [Revista revisada por pares]

England: Taylor & Francis Group

Texto completo disponible

Citas Citado por

Acciones

Título:
Successful use of tralokinumab for the treatment of atopic dermatitis on the genitals
Autor: Paolino, Giovanni ; Narcisi, Alessandra ; Carugno, Andrea ; Malagoli, Piergiorgio ; Di Nicola, Matteo R ; Foti, Antonio ; Bianchi, Vittoria G ; Locatelli, Andrea Gustavo ; Sena, Paolo ; Costanzo, Antonio ; Mercuri, Santo R ; Valenti, Mario
Materias: Adult ; Antibodies, Monoclonal - therapeutic use ; Atopic dermatitis ; Dermatitis, Atopic - drug therapy ; Dermatitis, Atopic - pathology ; Female ; Genital Diseases, Female - drug therapy ; Genital Diseases, Male - drug therapy ; genitals ; Humans ; Male ; Middle Aged ; Pruritus - drug therapy ; Pruritus - etiology ; Quality of Life ; Severity of Illness Index ; tralokinumab ; Treatment Outcome ; Young Adult
Es parte de: The Journal of dermatological treatment, 2024-12, Vol.35 (1), p.2351489-2351489
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Descripción: Genital involvement in atopic dermatitis(AD) can have a significant impact on the patient's quality of life. However, inspection of genital areas is not usually conducted during routine examination and patients may be reluctant to inform the clinician or show this area. to evaluate the efficacy of tralokinumab in AD patients with genital involvement. Adult patients with moderate/severe AD and genital involvement receiving tralokinumab have been analyzed. Primary endpoints were EASI, DLQI, PP-NRS, genital-IGA (g-IGA) and genital itching (GI) at week 16. out of 48 patients with moderate/severe AD under treatment with tralokinumab, 12 patients (25%) showed a genital involvement. Seven patients reported itching in the genital area (58%), while none reported a positive history of genital infections. Median scores at T0 were EASI 17.5, PP-NRS 8 and DLQI 14. After 16 weeks of treatment, we observed a median EASI of 3, a median PP-NRS of 1 and a median DLQI of 1. Finally, concerning the genital response, after 16 weeks of treatment, we observed a statistically significant decrease in mean GI and g-IGA scores. despite the small size of our sample, tralokinumab can be considered as a valid treatment option for AD with genital involvement.
Editor: England: Taylor & Francis Group
Idioma: Inglés

Enlaces

View this record in MEDLINE/PubMed

Volver a la lista de resultados

Anterior Resultado 3 Siguiente Ir a la siguiente página

Realización: Logos de Redes Sociales:

Successful use of tralokinumab for the treatment of atopic dermatitis on the genitals

Paolino, Giovanni ; Narcisi, Alessandra ; Carugno, Andrea ; Malagoli, Piergiorgio ; Di Nicola, Matteo R ; Foti, Antonio ; Bianchi, Vittoria G ; Locatelli, Andrea Gustavo ; Sena, Paolo ; Costanzo, Antonio ; Mercuri, Santo R ; Valenti, Mario

England: Taylor & Francis Group

Buscando en bases de datos remotas, por favor espere